CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


HP:0030357: Small cell lung carcinomaHPO

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (3)


Name (Synonyms) Correlation
drug2830 Talabostat Mesylate plus Pembrolizumab Wiki 1.00
drug759 Convalescent Plasma of patients with COVID-19 Wiki 1.00
drug3409 placebo (hartmann plus albumine) Wiki 1.00

Correlated MeSH Terms (4)


Name (Synonyms) Correlation
D055752 Small Cell Lung Carcinoma NIH 1.00
D018288 Carcinoma, Small Cell NIH 1.00
D018358 Neuroendocrine Tumors NIH 0.58
D011471 Prostatic Neoplasms NIH 0.50

Correlated HPO Terms (2)


Name (Synonyms) Correlation
HP:0100634 Neuroendocrine neoplasm HPO 0.58
HP:0012125 Prostate cancer HPO 0.50

There is one clinical trial.

Clinical Trials


1 Phase 1b/2 Study of BXCL701, a Small Molecule Inhibitor of Dipeptidyl Peptidases, Administered in Combination With the Anti-Programmed Cell Death 1 Monoclonal Antibody Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype

An open-label, multicenter, Phase 1b/2 study to determine the composite response rate of BXCL701 administered orally and daily, combined wit PEMBRO, in patients with mCRPC enrolled in Stage 2, with either Small Cell Neuroendocrine Prostate Cancer(SCNC)(Cohort A) or adenocarcinoma phenotype (Cohort B). This study will also assess other efficacy parameters as well as the safety of the combined treatment. This study will consist of two (2) stages. Lead-in Stage, in which the safety and tolerability of the combination will be assessed and confirmed. And the Efficacy Stage, in which patients will be treated with BXCL701 combined with PEMBRO.

NCT03910660 Prostate Cancer Neuroendocrine Tumors Small Cell Carcinoma Drug: Talabostat Mesylate plus Pembrolizumab
MeSH:Prostatic Neoplasms Neuroendocrine Tumors Carcinoma, Small Cell Small Cell Lung Carcinoma
HPO:Neuroendocrine neoplasm Prostate cancer Prostate neoplasm Small cell lung carcinoma

Primary Outcomes

Description: Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 criteria; circulating tumor cell (CTC) conversion from >5/7.5 mL to <5/7.5 mL12; and a greater than 50% prostate-specific antigen (PSA) decline from baseline.

Measure: Estimate the composite response rate of the combination of BXCL701 + PEMBRO

Time: up to 36 months

Secondary Outcomes

Description: The median time frame with progression-free survival with the use of BXCL701 in combination with Pembro determined by radiographic evidence.

Measure: Estimate the median radiographic progression-free survival (rPFS) of the combination of BXCL701 and PEMBRO in Cohort A and B

Time: up to 36 months

Description: The median time frame with progression-free survival with the use of BXCL701 in combination with Pembro

Measure: Estimate the median PSA progression-free survival (PSA PFS) of the combination of BXCL701 and PEMBRO in Cohort A and B.

Time: up to 36 months

Description: The median time frame with overall survival with the use of BXCL701 in combination with Pembro

Measure: Estimate the median overall survival (OS) of the combination of BXCL701 and PEMBRO in Cohort A and B.

Time: up to 36 months

Description: The timeframe in which the tumor reacts to BXCL701 in combination with Pembro

Measure: Estimate the median duration of response (DOR) of the combination of BXCL701 and PEMBRO in Cohort A and B.

Time: up to 36 months

Description: Determines the frequency and severity of known and unknown adverse events with the use of BXCL701 in combination with Pembro

Measure: Determine the risk profile of the use of BXCL701 in combination with PEMBRO.

Time: up to 36 months


HPO Nodes